FDA trumpeted its support for novel clinical trial designs using master protocols with a review article in the New England Journal of Medicine authored by top drug review officials.
Master Protocols Are Both Welcome And Inevitable – US FDA's Woodcock
Center for Drug Evaluation and Research Director Janet Woodcock continues to promote innovation in clinical trial design with a review of master protocols in the New England Journal of Medicine.
